Answers are grounded in this paper and cite their sources.
The reader will come to: • Melatonin is a medicine, not a supplement, and requires regulated prescribing. • Behavioural sleep strategies are essential, with melatonin used only as an adjunct. • Off-label use demands caution, informed consent, and structured planning. • Unregistered products’ quality varies widely, and only the regulatory authority-approved formulations should be used. • Paediatric overdose risks are rising due to unregulated products, highlighting the need for clinician-led prescribing and parental education. Behavioural sleep problems are common in children. The challenges with establishing and maintaining good sleep hygiene may prove challenging to overcome based on environmental issues such as the liberal availability of electronic media from a young age, permissive parenting, difficult family dynamics and limited parental/carer understanding of a child’s sleep needs as they progress through childhood and adolescence. Melatonin is inexpensive, easily accessible, in high demand from the community and, at its simplest, may be perceived as a harmless “silver bullet” for “sleep problems”. Clinicians are encountering children already using melatonin, sometimes with minimal behavioural support and misconceptions about its safety. This article provides frontline clinicians with an evidence-based overview of melatonin’s role in paediatric care, emphasising its approved indications, the dangers of unregulated products and the risks of unsupervised use.
No takes yet. Share an insight, caveat, or question.
Ohn et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: